Liquid Brain: Neuromorphic sensing and computing platform for high-throughput screening of antibody developability

药物开发成本正在上升，药物研发效率正在下降，这增加了生物技术和制药公司、医疗保健提供者的成本，并降低了全球患者的负担能力和可及性。90%的候选药物在临床开发阶段失败。生物制剂临床阶段失败的三分之一是由于可开发性差，每开发一种药物的成本约为4.5亿美元。在药物发现的关键阶段部署的高通量筛选技术用于针对药物靶点评估数千种潜在药物。然而，与药物可开发性相关的关键生物物理特性的全面评估仍然受到资源和时间限制的严重限制，包括有限的材料可用性，特别是生物制剂。Apoha是由Shamit Shrivastava博士（Apoha核心平台技术的发明者，牛津大学前博士后研究员）和Anshika Srivastava（高盛前执行董事/副总裁）于2021年创立的隐形阶段初创公司（英国中小企业）。我们的使命是在脑物质物理学的启发下，为传感和计算创造一种强大且可持续的新范式。我们正在开发一种“液体大脑”，这是一种基于神经形态液体的技术，当它暴露在化学物质中时，可以模仿神经元的活动。我们创新背后的基础科学被《科学美国人》在2018年强调为“可以改变一切的科学革命”。在Innovate UK的支持下，我们将通过开发一种神经形态传感和计算平台，对潜在的生物物理特性进行高通量筛选，将我们的“液体大脑”平台技术应用于抗体可开发性差的挑战。我们将把我们的专有和专利硬件与先进的神经形态算法结合起来，根据抗体的发展潜力对其进行排名。我们的创新直接解决了英国创新战略2021中强调的全球变革性研究的关键障碍，即药物研发效率下降和药物开发成本上升。

Drug development costs are rising and pharmaceutical R&D efficiency is falling, increasing costs for BioTech and Pharma companies, healthcare providers, and reducing affordability and accessibility for patients worldwide.90% of drug candidates fail during clinical-stage development. Poor developability accounts for one third of clinical-stage failures of biologics, costing approximately USD450M per drug developed. High-throughput screening technologies deployed in the critical hit-to-lead phase of drug discovery are used to evaluate thousands of potential drugs against the drug target. Yet, comprehensive assessment of key biophysical properties associated with drug developability remains severely restricted by resource and time constraints, including limited material availability, particularly for biologics.Apoha is a stealth-stage start-up (UK SME), founded in 2021 by Dr Shamit Shrivastava (inventor of Apoha's core platform technology; ex-postdoctoral researcher, University of Oxford) and Anshika Srivastava (ex-Executive Director/Vice President, Goldman Sachs). Our mission is to create a new paradigm for sensing and computing that is powerful and sustainable at scale, inspired by the physics of brain matter.We are developing a "liquid brain", a neuromorphic fluid-based technology that mimics neuron-like activity when it is exposed to a chemical. The fundamental science behind our innovation was highlighted by Scientific American in 2018 as a "Revolution in Science that could change everything".With Innovate UK support, we will apply our "liquid brain" platform technology to the challenge of poor antibody developability, by developing a neuromorphic sensing and computing platform for high-throughput screening of underlying biophysical properties. We will combine our proprietary and patented hardware with cutting-edge neuromorphic algorithms trained to rank antibodies based on their developability potential.Our innovation directly addresses a key barrier to global transformative research highlighted in the UK Innovation Strategy 2021, that of declining pharmaceutical R&D efficiency and the rising cost of drug development.